Timing of reported systolic dysfunction with mavacamten relative to echocardiographic monitoring schedules: a FAERS disproportionality analysis
Year: 2026
Type: preprint
Abstract: Aim: In April 2025, the US prescribing information for mavacamten allowed eligible stable patients to extend echocardiographic monitoring to every 6 months from week 12. We examined when systolic dysfunction-related events are reported relative to this schedule. Methods: We analyzed US Food and Drug Administration Adverse Event Reporting System (FAERS) reports from April 2022 to June 2026 listing mavacamten as primary or secondary suspect (n = 4953), using disproportionality analysis with restricted comparators. Time to onset was calculated after additional deduplication across case identifiers. Reporting density (events/30 days) was compared across monitoring intervals, restricted to reports with ≥12 months or ≥2 years of potential observation. Results: Ejection fraction decreased had the highest reporting odds ratio (ROR) among clinical terms with ≥10 reports (n = 181; ROR 53.64, 95% confidence interval [CI] 46.10–62.41) and remained elevated against a cardiomyopathy-spectrum comparator (ROR 3.23, 95% CI 2.23–4.67). Among 88 cases (median time to onset 125.0 days), reporting density fell from 13.21 events/30 days in the first 12 weeks to 3.79 from week 12 to month 9, without a clear difference from months 9–12 (rate ratio 1.14, 95% CI 0.48–3.01). With ≥2 years of potential observation, density was higher from week 12 to month 12 than in months 12–24 (rate ratio 3.68, 95% CI 1.38–11.40; 6 later events). Conclusion: Reporting density was highest in the first 12 weeks, with no clear further decline during the rest of the first year. This period warrants evaluation in eligible cohorts with documented echocardiography.
Source: Authorea
Authors: Xinxin Chen, Zifu Chen, Ying Kang
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7236587046
